Adding mild heat therapy to standard treatment for advanced head and neck cancer
Tests the safety of heat therapy added to radiotherapy in head and neck cancer.
Plain-language title generated from the registry record
Registry title: Thermotherapy for Head and Neck Cancer Patients
Key facts
- Where
- Rotterdam, NetherlandsSee the site
- Phase
- Phase 1
Where in Netherlands
- Erasmus Medical CenterRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT07690618
- Record updated
- 2 September 2026
- Original description
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). Tumor recurrence remains common despite chemoradiotherapy, highlighting the need for treatment intensification. Thermotherapy, which increases tumor temperature to 39-45°C, may enhance the effect of the treatment.Read full original descriptionShow less
Thermotherapy for Locally Advanced Head and Neck Cancer Patients in Primary Setting - a Phase I Dose-finding Study
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). Tumor recurrence remains common despite chemoradiotherapy, highlighting the need for treatment intensification. Thermotherapy, which increases tumor temperature to 39-45°C, may enhance the effect of the treatment.
The study consists of two components: (1) a dose-escalation cohort in patients receiving definitive chemoradiotherapy, using a Time-to-Event Bayesian Optimal Interval (TiTE-BOIN) design to determine the RP2D based on dose-limiting toxicities (DLTs) and treatment tolerability; and (2) a parallel cohort of patients receiving radiotherapy alone, in whom thermotherapy is administered at dose levels previously shown to be safe and tolerable in the chemoradiotherapy cohort to evaluate tolerability in this patient population.
Besides the safety and tolerability of the thermotherapy RP2D, the secondary objectives include evaluation of safety in patients receiving radiotherapy alone, as well as exploratory assessment of tumor control and survival outcomes.
This study aims to support the development of safe and feasible thermotherapy-based treatment strategies to improve locoregional control and outcomes in patients with LAHNSCC.
Exclusion: Patients previously treated by radiation on the same target volume; Any condition or circumstance potentially hampering compliance with the follow-up schedule.
For eligibility to participate in this study in the primary cohort, a patient must meet all following criteria:; Age ≥ 18 years; WHO 0-1; Maximal mouth opening of ≥ 40 mm for women and ≥ 45 mm for men before treatment; Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx proven by cytology/histology; Locally advanced disease (stage III-IV); Curative intent treatment with radiotherapy and concurrent platinum based chemotherapy in primary setting; Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician; Written informed consent; For the parallel secondary cohort, the same inclusion criteria must be met, except for the standard of care treatment:; Curative intent treatment with radiotherapy monotherapy in primary setting.